2 not yet recruiting, 2 recruiting, 1 active not recruiting, 1 completed. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow SHR-A2009: new trials by email Literature Review of SHR-A2009 trials Research Report on SHR-A2009
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase Ib Study of HS-10504 Combined Therapy in NSCLC HS-10504, SHR-A2009, HS-20122 - Lung Cancer | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 400 | 2026-03-30 | 2026-02-17 |
| Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer SHR-A1811, SHR-A1921, SHR-A2009 - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Fudan University | 160 | 2024-10-21 | 2026-09-03 |
| Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC SHR-A2009, SHR-A1921 - NSCLC | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 30 | 2024-06-01 | 2024-06-20 |
| SNF Platform Study of HR+/ HER2-advanced Breast Cancer PIK3CA inhibitor, AKT inhibitor, Carrelizumab - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 620 | 2022-12-30 | 2024-10-04 |
| The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors SHR-A2009 - Advanced Solid Tumor | Phase 1 | Completed | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 19 | 2022-07-21 | 2024-12-27 |
| A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors SHR-A2009 - Advanced Solid Tumors | Phase 1 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 176 | 2022-01-04 | 2026-07-16 |
Breast Neoplasms (2) · Lung Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Fudan University (2) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Henan Cancer Hospital (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1)
China (5) · Japan (1) · South Korea (1)